Menu

FDA Approves Drug to Ease Symptoms of Opioid Withdrawal

Lucemyra is the first non-opioid drug to be approved in the U.S. specifically for this purpose.

May 17, 2018
Catherine Offord

ISTOCK, SDOMINICKThe US Food and Drug Administration (FDA) has approved the first non-opioid drug for treatment of the symptoms of opioid withdrawal. Announcing the move in a press statement yesterday (May 16), the agency noted that Lucemyra (lofexidine hydrochloride) is intended to help adults who abruptly stop taking the addictive painkillers, and is only approved for treatment for up to two weeks.

“It won’t completely eliminate symptoms of withdrawal,” Mark Pirner, the senior medical director at Lucemyra manufacturer US WorldMeds, tells STAT News. “But for places and people where withdrawal is perpetuating higher opioid use, then Lucemyra is an appropriate therapy.”

See “The Quest for Safer Opioid Drugs

In 2016, opioid-related overdoses in the U.S. led to more than 42,000 deaths—a toll that exceeded the number of people killed in car crashes. The drugs are notoriously addictive, with withdrawal symptoms including extreme nausea, vomiting, and anxiety.

“We know that the physical symptoms of opioid withdrawal can be one of the biggest barriers for patients seeking help and ultimately overcoming addiction,” FDA Commissioner Scott Gottlieb says in the statement. “The fear of experiencing withdrawal symptoms often prevents those suffering from opioid addiction from seeking help.”

While there are currently some other approved drugs that mitigate withdrawal symptoms, many are themselves opioids, such as buprenorphine, or target specific symptoms alongside underlying opioid dependency.

The new compound itself is not without side effects; Lucemyra can cause dizziness as well as low blood pressure and heart rate. The FDA has required another 15 studies to assess the drug’s safety in situations not described in the current approval, including use in children and use that exceeds 14 days.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.